Argitalpenak (8) EVA MUNARRIZ CUEZVA argitalpenak

2024

  1. Effect of antipsychotic drugs on group II metabotropic glutamate receptor expression and epigenetic control in postmortem brains of schizophrenia subjects

    Translational Psychiatry, Vol. 14, Núm. 1

2023

  1. Inhibition of Prolyl Oligopeptidase Restores Prohibitin 2 Levels in Psychosis Models: Relationship to Cognitive Deficits in Schizophrenia

    International Journal of Molecular Sciences, Vol. 24, Núm. 7

2021

  1. Characterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia

    Pharmacological Reports, Vol. 73, Núm. 4, pp. 1136-1146

  2. Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways

    Frontiers in Pharmacology, Vol. 12

2017

  1. Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia

    Neuropharmacology, Vol. 116, pp. 196-207

  2. The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia

    European Neuropsychopharmacology, Vol. 27, Núm. 2, pp. 180-191

2013

  1. Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia.

    Translational psychiatry, Vol. 3

2012

  1. Regulation of munc18-1 and syntaxin-1A interactive partners in schizophrenia prefrontal cortex: Down-regulation of munc18-1a isoform and 75 kDa SNARE complex after antipsychotic treatment

    International Journal of Neuropsychopharmacology, Vol. 15, Núm. 5, pp. 573-588